Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447910 · ClinicalTrials.gov registry record
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 21
- Enrollment target
NCT05447910: Clinical Trial study, sponsored by Mayo Clinic.
NCT05447910 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447910 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to study to collect tissue samples from patients with early stage hormone receptor-positive HER2-negative breast cancer.
Primary Outcome
Tissue samples from patients with early-stage hormone receptor-positive HER2-negative breast cancer will be collected to compare differences.
Interventions
- PROCEDURE Biospecimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2023-09-27 |
Why NCT05447910 stopped before completion
NCT05447910 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT05447910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05447910 about?
NCT05447910 is a clinical study titled "Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer". The purpose of this study is to study to collect tissue samples from patients with early stage hormone receptor-positive HER2-negative breast cancer.
What is the current status of trial NCT05447910?
This trial is currently terminated. The enrollment target is 21 participants. The study started on 2022-07-21. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT05447910?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT05447910?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI